TSBX: רווח נקי למניה (EPS TTM) Turnstone Biologics Corporation

Colossal R&D expenditures create a formidable barrier to entry in the sector, as reflected in the TTM net income per share trend, where the latest value is recorded as -2.02. Turnstone Biologics (TSBX) relies on inelastic demand in oncology, leveraging unique TIL lymphocyte selection. Simultaneously, the company is implementing robotic systems to accelerate clinical phases and automate sample preparation.

Exclusive patents for TIL-cell selection create a sustainable market barrier for Turnstone Biologics (TSBX). This metric is calculated as net income divided by the average number of shares, which offsets the impact of share issuances. Investors utilize this calculation to assess the business's actual ability to generate cash flow. This trend allows them to filter out market noise and one-off transactions. By analyzing the earnings per share over a rolling year, one can determine the fundamental value of the business.